加载中
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
收盘时
US$4.00
US$0.00 · 0.00%
盘后
US$4.00
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
日内区间
当前US$4.00
52周区间
当前US$4.00
盘中时间采用ET。市场数据可能有所延迟。
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
日内区间
当前US$4.00
52周区间
当前US$4.00
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 4208.2万 USD | 2440.1万 USD | 4399.9万 USD | 2368.9万 USD | — |
| 销售、一般及管理费用 | 3316.4万 USD | 3078.8万 USD | 1863.9万 USD | 347.3万 USD | 109.2万 USD |
| 营业费用 | 7524.6万 USD | 5518.9万 USD | 6263.8万 USD | 2716.2万 USD | 109.2万 USD |
| 利息收入 | 633.6万 USD | 799.8万 USD | 218.6万 USD | 570 USD | 2.35万 USD |
| 折旧和摊销 | 4.9万 USD | 9000 USD | — | — | — |
| 营业利润 | −7524.6万 USD | −5518.9万 USD | −6263.8万 USD | −2716.2万 USD | −109.2万 USD |
| 净利润 | −6865万 USD | −5240.3万 USD | −6036万 USD | −2573.8万 USD | 841.67万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$20.00
上涨空间 400.00%报告持有此股票敞口的交易所交易基金。
iShares Russell 2000 ETFIWM617.19万0.01%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF418.76万0.00%954亿 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO220.6万0.02%139.17亿 USD0.24%US$353.71-0.86%
Vanguard Russell 2000 ETFVTWO187.58万0.01%180亿 USD0.06%US$112.27-0.35%
iShares Micro-Cap ETFIWC73.82万0.06%13.17亿 USD0.60%US$181.66-0.73%
ALPS Medical Breakthroughs ETFSBIO48.32万0.25%1.91亿 USD0.50%US$53.85-2.16%
Vanguard Russell 2000 Growth ETFVTWG35.46万0.02%17亿 USD0.06%US$258.28-0.85%
iShares Russell 2500 ETFSMMD13.09万0.00%40.62亿 USD0.23%US$86.01-0.32%iShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCALPS Medical Breakthroughs ETFSBIOVanguard Russell 2000 Growth ETFVTWGiShares Russell 2500 ETFSMMDAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
